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ABSTRACT
Cancer  is  a disease  involving many genes,  consequently it  has
been difficult to design anticancer drugs that are efficacious over
a broad range of cancers. The robustness of cellular responses to
gene knockout and the need to reduce undesirable  side effects
also  contribute  to  the  problem  of  effective  anti-cancer  drug
design. To promote the successful selection of drug targets, each
potential target should be subjected to a systems biology scrutiny
to  locate  effective  and  specific  targets  while  minimizing
undesirable  side  effects.  The  gene  p53  is  considered  a  good
candidate for such a target because it has been implicated in 50%
of all  cancers and is considered to encode a hub protein that is
highly connected to other proteins. Using P53 as a test case, this
paper  explores  the  capacity  of  the  systems  biology  tool,
CellDesigner,  to aid in the selection of anticancer drug targets
and  to  serve  as  a  teaching  resource  for  human  resource
development. 
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1. INTRODUTION
Over the past decade, there has been a significant decrease
in  the  rate  that  new  anticancer  drug  candidates  are  being
translated  into  effective  therapies  in  the  clinic.  In  particular,
there has been a worrying rise in late-stage attrition in phase 2
and phase 3 [1]. Currently, the two single most important reasons
for this attrition, each of which account for 30% of failures are (i)
lack  of  efficacy  and  (ii)  clinical  safety  or  toxicology.  These
late-stage attrition rates are at the heart  of much of the relative
decline in productivity of the pharmaceutical industry resulting in
significant financial setbacks. In addition, because many patents
on the  current  generation  of marketed  drugs  will  expire  from
2010 onward, pharmaceutical companies will face the first fall in
revenue in four decades. 
With advances in human genome biology and the advent of
personalized  medicine,  new opportunities  for  the  discovery of
drug targets are arising. The fundamental challenge of anticancer
therapy is the need for agents that eliminate cancer cells with a
therapeutic index that is safely tolerated by the patient. However,
the selection of suitable anticancer drug targets is complicated by
the fact that over 100 genes have been shown to be involved in
the disease, rendering it necessary to develop multiple therapies.
In addition, the cell shows a remarkable degree of robustness, in
which impairment of the functions of some genes by mutation or
drug targeting can be rescued by the action of other genes.  For
example,  using genetic engineering techniques to knock out the
function  of  over  40%  of  the  approximately  6000  yeast  genes
one-by-one has little effect on cell growth in rich medium [2, 3].
The  transcription  factor  P53  is  encoded  by  a  tumor
suppressor  gene  that  can  arrest  the  cell  cycle  and  facilitate
apoptosis.  P53  functions  as  a  sensor  of  upstream  signals  that
reflect  DNA-damage   and  cellular  stresses  such  as   hypoxia,
providing  protection  against  tumor  growth,  and  the  action  of
oncogenes  (Myc,  Ras,  E1A,  ß-catenin)  [4,  5].  These  signals
activate  latent  p53  by enhancing its  DNA-binding  activity and
increasing its stability, resulting in increased levels of 10-100x of
the protein. Since enhanced levels of p53 lead to cell cycle-arrest
and apoptosis, it is of critical importance that normal cells keep
their p53 levels low. This can be accomplished by destabilization
of P53 by interaction with  the protein  Mdm2.  Interaction with
Mdm2 causes export  of P53 from the nucleus to the cytoplasm
where it  is  targeted  for proteosomal degradation by interaction
with a P53-specific E3 ubiquitin [6]. The gene encoding Mdm2
is activated by P53 but at a time that is relatively late in the cell
cycle providing a window of time where P53 can function.
P53 has  been  considered  a  suitable  target  for anticancer
therapies because of its widespread implication in about 50% of
all cases of cancer [7-9]. It is also a node protein with extensive
interaction partners (a hub) and high turnover rate [10]. As such,
its  function  may  not  easily  be  replaced  by  other  proteins
(knockout inviable)  [10]. Several strategies  have been explored
in  attempts  to  stabilize  P53  by preventing  or  diminishing  its
interaction  with  Mdm2 [11-18].  The  long term objective  is  to
improve the efficacy of P53 to promote cell apoptosis in cancer
cells. 
Given  the  promise  of  this  approach  and  the  substantial
body  of  mathematical  modeling  and  experimental  evidence
describing  the  cellular  oscillations  of the  P53-Mdm2 pair,  we
decided  to  explore  the  use  of  CellDesigner,  as  a  tool  for
evaluating  the  network  consequences  of  eliminating  the
interaction  of  Mdm2  with  P53.  CellDesigner  can  visualize,
model and simulate biochemical networks and can integrate with
existing databases such as KEGG, PubMed, BioModels [19]. 
2.   METHODS
2.1 Systems parameters
The  parameters  that  describe  the  initial  states  and
oscillatory nature of the p53-Mdm2 interaction in the normal cell
were  obtained  by combining  information  from several  sources
[20-23]. These parameters allow the partial differential equations
that govern the system  to be derived:
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Equations 1 describes the negative feedback loop (defined
as x) for P53 in which its activity decreases with time according
to  the  mass-action  binding  of Mdm2 to  P53  resulting  in  P53
ubiquitination  and  subsequent  proteasomal  degradation.
Equation 2 describes the transcriptional activity of p53 (defined
as y), depending on an initial  value and a production rate  that
decreases  with  time  as  Mdm2  activity  increases.  Equation  3
describes  the  transcriptional  activity  of  Mdm2  (yo)  which
decreases from an initial value because of the negative feedback
loop imposed by parameters described in the second equation. 
For these equations, the variables are derived from [21] the
initial  values  of  the  variables  are:  x  (0.20),  y (0.10),  and  yo
(0.20).  The  other  parameters  are:  αk is  the  rate  of
Mdm2-independent  degradation  of P53 and  the  P53-dependent
Mdm2  production  rate  (0);  αy is  the  Mdm2  degradation  rate
(0.8); βx is the P53 production rate (0.9); βy is the P53-dependent
MDM2 production rate (1.1);  αo is the maturation rate (0); k is
the P53 threshold for degradation by MDM2 (0.0001) and  ξ is
equal to 1. On addition of a drug that completely eliminates the
P53-Mdm2  interaction,  factors    are  added  to  the  x  and  yo
equations,  where  δ is  the  drug  concentration  (0.17  arbitrary
units). 
2.2 Pathways and Use of CellDesigner
Pathways  describing  the  interaction  of  P53  with  Mdm2
were uploaded  from KEGG [24] into CellDesigner   using the
intuitive  interface  comprised  of   graphical  notation,  model
description  and  an  application  integration  environment  as
described [19, 25-27].
3. RESULTS
Two network models for the interaction of P53 and Mdm2
were generated by CellDesigner. The first network illustrates the
negative feedback loop that models the experimentally observed
time-delayed oscillatory nature of both P53 and Mdm2 (Fig. 1A).
The second network introduces a drug-induced inhibition of the
interaction  between  P53  and  Mdm2 that  in  turn  impedes  the
ubiquitination  of  P53  and  its  subsequent  degradation  by
proteosomes (Fig. 1B). The drug is hypothetical and is assumed
to cause significant inhibition of the P53/Mdm2 interaction.
Using parameters described in Methods and the networks
shown in Fig. 1, CellDesigner was used to predict fluctuations of
P53 and Mdm2 for 400 min in normal cells (Fig. 2A) and for 200
min in cells with the drug application (Fig. 2B). The application
successfully predicted the time-delayed, oscillatory profiles of the
interacting partners in the normal cell with the characteristic 20
min  periodicity  of   fluctuation  (Fig.  2A)  and  predicted  a
damping out of both P54 and Mdm4 after the addition of the drug
(Fig.  2B) that  has  been observed in  mathematical models [29,
30]. 
Figure 1: Model of the interaction of P53 with Mdm2 and the resulting
perturbations in the system predicted by CellDesigner in the absence
(A) or  presence (B) of a hypothetical drug that blocks the interaction
between the two proteins. P53* = P53 precursor,    Mdm2*  = Mdm2
precursor,  P53(Mdm2)  =  p53-dependent  Mdm2  production  rate,
Mdm2(P53) = Mdm2-dependen p53 production rate.
Figure  2:  Prediction  of  the  changes  in  the  amount  (amplitude  in
arbitrary units) of P53 and Mdm2 per cell as a function of time without
(A)  and with (B)  addition  of   a  hypothetical  drug  that  blocks  the
interaction of the two proteins. The curves were generated using the
flow diagram shown in Figure 1.
4. DISCUSSION
The time-delayed, oscillatory behavior of P53 and Mdm2 in
the normal cell  has been observed experimentally [29] and has
been  modeled  theoretically  [28,  30-33].  In  addition,
mathematical  models  have  been  developed  that  predict
damping-out of concentrations of P53 following the perturbation
of the interaction of P54 with Mdm2 via a naturally occurring
mutation  [38]  or  after  treatment  with  the  small  molecule
inhibitor  Nutlin-3  [36].  The  problem  with  these  theoretical
models is that they are essentially “static”. CellDesigner is also
able to successfully model the behavior of P54 and Mdm2 in the
normal cell (Figs. 1A and 2A) and can also predict damping out
when a theoretical drug that prevents P54/Mdm2  interaction is
introduced  into  the  system   (Figs  1B  and  2B).  However,  in
contrast  to  the  previous  models,  CellDesigner  integrates
pathway  visualization  with  analysis  using  Systems  Biology
Markup  Language  [38],  providing  a  more  dynamic  model  of
cellular  processes  through the incorporation of gene expression
data,  subcellular  localization  information,  time-dependent
behavior,  chemical  reactions,  kinetic  equations  etc.  a  one stop
shopping  environment.  Also,  because  CellDesigner  is  open
source,  custom designed plug-ins  can be added when required.
CellDesigner  has been used to predict  suitable  drug targets  for
for methicillin-resistant  bacteria  [39],  but  this  is  the  first  time
that it has been used to examine anti-cancer targets. Because it is
open source and manageable in a user-friendly fashion, we have
found CellDesigner  to be an excellent  aid for teaching systems
biology at the undergraduate and graduate level. 
Other open source services similar to CellDesigner include
PathwayStudio  [40],  Cytoscape  [41],  VisANT  [42],
BiologicalNetworks  [43]  and  Teranode  Pathway  Analytics
(available  at  www.teranode.com/).  As increasing  abundance  of
experimental  data  from  high-throughput  experimental  biology
becomes available and as the cost, efficiency and accuracy of this
data improves, greater emphasis will  be put on systems biology
applications  such as Celldesigner and others for connecting vast
amounts of data and but also capturing usable knowledge in the
form of biologically valid  relations  that  research scientists  can
apply. 
The  modeling  of  the  P53/Mdm2  interaction  network
presented  here  represents  a  simplistic  first  step  for  evaluating
anticancer drug targets  by CellDesigner.  But it  should serve as
the starting point for several interesting lines of further  inquiry
including the evaluation of the interactions of P53 with Akt [44],
p14ARF and ATM [20], Pten and Pip3 [45] and other members
of its  interactome.  This  information  needs   to  be  explored  in
order  to  provide  a  more  comprehensive  understanding  of  the
potential  of  the  P53/Mdm2  interaction  as  a  anticancer  drug
target.
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